Skip to content

Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans

Cédric M. Hysek, Yasmin Schmid, Anna Rickli, Linda D. Simmler, Massimiliano Donzelli, Eric Grouzmann, Me Liechti

British Journal of Pharmacology March 8, 2012 DOI: 10.1111/j.1476-5381.2012.01936.x (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized, double-blind, placebo-controlled, four-period crossover study Peer reviewed
Sample size 16
Population Healthy subjects
Interventions Carvedilol MDMA
Dose 50 mg carvedilol, 125 mg MDMA
Topics MDMA
Keywords Carvedilol Placebo Pharmacology Heart rate Adverse effect Crossover study Antagonist Anesthesia Hyperthermia Drug Blood pressure
Citations 81
Key points Carvedilol reduced MDMA-induced elevations in blood pressure, heart rate, and body temperature but did not affect the subjective effects of MDMA.

Abstract

Background: AND PURPOSE The use of ±3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is associated with cardiovascular complications and hyperthermia. EXPERIMENTAL APPROACH We assessed the effects of the α 1 ‐ and β‐adrenoceptor antagonist carvedilol on the cardiostimulant, thermogenic and subjective responses to MDMA in 16 healthy subjects. Carvedilol (50 mg) or placebo was administered 1 h before MDMA (125 mg) or placebo using a randomized, double‐blind, placebo‐controlled, four‐period crossover design. KEY RESULTS Carvedilol reduced MDMA‐induced elevations in blood pressure, heart rate and body temperature. Carvedilol did not affect the subjective effects of MDMA including MDMA‐induced good drug effects, drug high, drug liking, stimulation or adverse effects. Carvedilol did not alter the plasma exposure to MDMA.

Conclusions: AND IMPLICATIONS α 1 ‐ and β‐Adrenoceptors contribute to the cardiostimulant and thermogenic effects of MDMA in humans but not to its psychotropic effects. Carvedilol could be useful in the treatment of cardiovascular and hyperthermic complications associated with ecstasy use.

Explore topics